Register for email alerts and news feeds:
This journal | BMJ Group
rss
Annals of the Rheumatic Diseases 1997;56:5-11; doi:10.1136/ard.56.1.5
Copyright © 1997 BMJ Publishing Group Ltd & European League Against Rheumatism.

Annals of the Rheumatic Diseases, 1997, Vol 56, 5-11


REVIEWS

New methods of treatment in an experimental murine model of systemic lupus erythematosus induced by idiotypic manipulation

Y Shoenfeld, I Krause and M Blank
Department of Medicine B, Sheba Medical Centre, Tel-Aviv University, Israel.

In this article we have presented our experiences and those of others with various experimental and novel treatments in an experimental model of murine SLE, induced by immunisation with pathogenic anti-DNA antibody (fig 4). Many of the treatments (summarised in the table) were highly effective in ameliorating clinical, serological, and histological manifestations of the disease. According to our results, it seems that hormonal treatments--such as testosterone metabolites, anti-oestrogens, or bromocriptine--as well as immunomodulation with IVIG or anti-CD4 antibodies, hold the most promising potential for application in lupus patients. We believe, therefore, that these types of treatment should receive high priority in human trials. It should be emphasised, however, that the timing of treatment may be critical, since several treatments were effective when used before or during the induction of the disease. This limitation may pose difficulty for human application, since the aetiology of SLE is still obscure and is probably multifactorial38; therefore it is not yet possible to identify patients at risk of developing SLE. Nevertheless, those treatments which proved to be effective might be used early in the course of the disease in lupus patients and hence influence the outcome of the disease, or may even induce partial or complete remission.


© 1997 by the Annals of the Rheumatic Diseases

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This article has been cited by other articles:

  • Ehrenfeld, M, Blank, M, Shoenfeld, Y, Hidvegi, M (2001). AVEMAR (a new benzoquinone-containing natural product) administration interferes with the Th2 response in experimental SLE and promotes amelioration of the disease. Lupus 10: 622-627 [Abstract]  
  • Strand, V (2001). Monoclonal antibodies and other biologic therapies. Lupus 10: 216-221 [Abstract]  
  • Levy, Y., Sherer, Y., Ahmed, A., Langevitz, P., George, J., Fabbrizzi, F., Terryberry, J., Meissner, M., Lorber, M., Peter, J. B, Shoenfeld, Y. (1999). A study of 20 SLE patients with intravenous immunoglobulin clinical and serologic response. Lupus 8: 705-712 [Abstract]  

This Article

Services
Citing Articles
Google Scholar
PubMed
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

BMJ Careers - Latest Rheumatology Jobs

Rheumatology Jobs